NovoCure (NVCR) Cash from Operations Growth (5y) (2019 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | NovoCure | 1.90 Bn | 1.47 Bn | 135.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -22.51% |
| Dec 31, 2025 | -18.50% |
| Sep 30, 2025 | -7.85% |
| Jun 30, 2025 | -26.59% |
| Mar 31, 2025 | -82.46% |
| Dec 31, 2024 | -20.07% |
| Sep 30, 2024 | -6.99% |
| Jun 30, 2024 | -16.97% |
| Mar 31, 2024 | -48.89% |
| Dec 31, 2023 | -23.44% |
| Sep 30, 2023 | -40.25% |
| Jun 30, 2023 | -24.86% |
| Mar 31, 2023 | 0.12% |
| Dec 31, 2022 | -5.05% |
| Sep 30, 2022 | 54.50% |
| Jun 30, 2022 | 36.18% |
| Mar 31, 2022 | 32.80% |
| Dec 31, 2021 | 24.98% |
| Sep 30, 2021 | 22.23% |
| Jun 30, 2021 | 23.65% |
| Mar 31, 2021 | 20.81% |
| Dec 31, 2020 | 32.26% |
| Sep 30, 2020 | 27.74% |
| Jun 30, 2020 | 20.58% |
| Mar 31, 2020 | 15.65% |
| Dec 31, 2019 | 19.09% |